Ambroxol-Chemopharm, syrup 15 mg/5 ml 100 ml

Mucolytic agent, stimulates prenatal lung development (increases synthesis, secretion of surfactant and blocks its breakdown).

It has secretomotor, secretolytic and expectorant action; stimulates serous gland cells of the mucous membrane of the bronchi, increases the mucous secretion and secretion of surfactant (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and increasing the release of lysosomes from Clark cells, reduces the viscosity of sputum.

It increases motor activity of micturate epithelium, increases mucociliary transport.

After oral administration the action comes in 30 minutes and lasts for 6-12 hours.

Absorption is high (by all routes of administration), maximum concentration in blood plasma (Tcmax) – after 2 hours, binding to plasma proteins – 80%. It penetrates through the blood-brain barrier (BBB), placental barrier, excreted with breast milk.

Metabolism – in liver, forms dibromanthranilic acid and glucuron conjugates. Period of half-life excretion (T1/2) – 7-12 hours. Renal excretion: 90% as water-soluble metabolites, unchanged – 5%.

Half-life is increased in severe chronic renal failure, but does not change in liver function disorders.

Indications

Diseases of the respiratory tract with the release of viscous sputum: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty in sputum discharge, bronchiectasis.

Pharmacological effect

A mucolytic agent that stimulates the prenatal development of the lungs (increases the synthesis and secretion of surfactant and blocks its breakdown).

It has secretomotor, secretolytic and expectorant effects; stimulates the serous cells of the glands of the bronchial mucosa, increases the content of mucous secretions and the release of surfactants

substances (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum.

By activating hydrolyzing enzymes and enhancing the release of lysosomes from Clark cells, it reduces the viscosity of sputum.

Increases the motor activity of the ciliated epithelium, increases mucociliary transport.

After oral administration, the effect occurs within 30 minutes and lasts for 6-12 hours.

Absorption is high (for any route of administration), maximum concentration in blood plasma (Tmax) is after 2 hours, binding to plasma proteins is 80%. Penetrates the blood-brain barrier (BBB), the placental barrier, and is excreted in breast milk.

Metabolism – in the liver, forms dibromanthranilic acid and glucuronic conjugates. The half-life (T1/2) is 7-12 hours. Excreted by the kidneys: 90% in the form of water-soluble metabolites, unchanged – 5%.

The half-life increases in severe chronic renal failure, but does not change in cases of impaired liver function.

Special instructions

Should not be combined with antitussive drugs that impede the removal of sputum.

Active ingredient

Ambroxol

Composition

5 ml of syrup contains the active ingredient:

Ambroxol hydrochloride 15 mg;

Excipients:

Benzoic acid

Glycerol 85%

Sorbitol 70%

Hyethylose (hydroxyethylcellulose 6000 mPas)

Raspberry flavor

Purified water

Pregnancy

Preclinical trials and extensive clinical experience have not revealed any undesirable effects of drug treatment during pregnancy.

However, general rules for prescribing medications should be followed, especially in the first trimester. Lazolvan® passes into breast milk, but in therapeutic doses does not have a negative effect on the child.

If it is necessary to use Lazolvan® in the II–III trimesters of pregnancy, the potential therapy for the mother and the possible risk to the fetus should be assessed

Contraindications

Hypersensitivity to all components of the drug; rare hereditary diseases, such as:

galactose intolerance, lactase deficiency or glucose-galactose malabsorption (for effervescent tablets),

pregnancy (first trimester), phenylketonuria (for effervescent tablets); children up to 12 years of age (effervescent tablets).

Side Effects

Allergic reactions: skin rash, urticaria, angioedema, in some cases – allergic contact dermatitis, anaphylactic shock.

Rarely – weakness, headache, diarrhea, dry mouth and respiratory tract, exanthema, rhinorrhea, constipation, dysuria. With long-term use in high doses – gastralgia, nausea, vomiting.

Interaction

Compatible with drugs that inhibit labor.

Combined use with antitussive drugs leads to difficulty in sputum discharge while reducing cough.

Increases the penetration of amoxicillin, cefuroxime, erythromycin and doxycycline into the bronchial secretions.

Overdose

Symptoms: possible – nausea, vomiting, diarrhea, dyspepsia, gastralgia.

Treatment: induction of vomiting, gastric lavage in the first 1–2 hours after taking the drug; intake of fat-containing foods, symptomatic therapy.

Storage conditions

List B.

Syrup – store in a place protected from light at a temperature of 15 to 25 ° C.

Keep out of the reach of children!

Shelf life

5 years.

Do not use after the expiration date stated on the package.

Manufacturer

Hemofarm A.D., Serbia